Form 4: Insmed Director Carol Schafer Receives RSU Grant
Statement of Changes in Beneficial Ownership
Insmed Incorporated director Carol Schafer was granted 3,305 restricted stock units as part of standard equity compensation.
Summary
- Director Carol Schafer acquired 3,305 restricted stock units (RSUs) in Insmed Incorporated.
- The grant occurred on May 13, 2026, for no monetary consideration.
- Following this transaction, the reporting person holds a total of 66,622 shares of common stock.
- The RSUs are subject to vesting conditions based on continued board service and meeting attendance requirements.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Transparent disclosure of director equity holdings.
Negatives
- None identified; this is a routine equity grant disclosure.
Risks
- Vesting of the RSUs is contingent upon the director remaining on the board and meeting specific attendance thresholds (75% of meetings).
Future Outlook
The RSUs will vest in full on the first anniversary of the grant date, provided the director remains on the board and meets attendance requirements.
Industry Context
StockSavvy.ai notes that this filing represents standard corporate governance practice for biotechnology companies, where equity grants are used to incentivize board members and align their interests with long-term shareholder value.
Comparison to Industry Standards
- The use of RSU grants for board compensation is consistent with standard practices among mid-cap biotechnology firms.
- Vesting schedules tied to board tenure and meeting attendance are common governance mechanisms to ensure active director participation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Establishment of a Limited Power of Attorney for SEC reporting purposes. | 08/06/2025 | Facilitates efficient and timely regulatory filings for the director. |
Stakeholder Impact
- Minimal impact on shareholders; reflects standard director compensation practices.
Next Steps
- Vesting of the 3,305 RSUs on the first anniversary of the grant date, subject to service and attendance conditions.
Key Dates
| Date | Description |
|---|---|
| 08/06/2025 | Date of execution for the Limited Power of Attorney. |
| 05/13/2026 | Date of the RSU grant and earliest transaction. |
| 05/15/2026 | Date of filing for the Form 4. |
Keywords
Insmed, INSM, Form 4, Director Compensation, Equity Grant, Insider Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.